252 related articles for article (PubMed ID: 31690781)
1. Infantile inflammatory myofibroblastic tumors: clinicopathological and molecular characterization of 12 cases.
Lopez-Nunez O; John I; Panasiti RN; Ranganathan S; Santoro L; Grélaud D; Wu T; Buccoliero AM; Casanova M; Alaggio R; Surrey LF
Mod Pathol; 2020 Apr; 33(4):576-590. PubMed ID: 31690781
[TBL] [Abstract][Full Text] [Related]
2. Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors.
Hornick JL; Sholl LM; Dal Cin P; Childress MA; Lovly CM
Mod Pathol; 2015 May; 28(5):732-9. PubMed ID: 25612511
[TBL] [Abstract][Full Text] [Related]
3. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours.
Yamamoto H; Yoshida A; Taguchi K; Kohashi K; Hatanaka Y; Yamashita A; Mori D; Oda Y
Histopathology; 2016 Jul; 69(1):72-83. PubMed ID: 26647767
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic and Genomic Characterization of Inflammatory Myofibroblastic Tumors of the Head and Neck: Highlighting a Novel Fusion and Potential Diagnostic Pitfall.
Kerr DA; Thompson LDR; Tafe LJ; Jo VY; Neyaz A; Divakar P; Paydarfar JA; Pastel DA; Shirai K; John I; Seethala RR; Salgado CM; Deshpande V; Bridge JA; Kashofer K; Brčić I; Linos K
Am J Surg Pathol; 2021 Dec; 45(12):1707-1719. PubMed ID: 34001695
[TBL] [Abstract][Full Text] [Related]
5. Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements.
Chang JC; Zhang L; Drilon AE; Chi P; Alaggio R; Borsu L; Benayed R; Travis WD; Ladanyi M; Antonescu CR
J Thorac Oncol; 2019 May; 14(5):825-834. PubMed ID: 30550870
[TBL] [Abstract][Full Text] [Related]
6. Identification of a Novel MAN1A1-ROS1 Fusion Gene Through mRNA-based Screening for Tyrosine Kinase Gene Aberrations in a Patient with Leiomyosarcoma.
Suehara Y; Kohsaka S; Hayashi T; Akaike K; Kurisaki-Arakawa A; Sato S; Kobayashi E; Mizuno S; Ueno T; Morii T; Okuma T; Kurihara T; Hasegawa N; Sano K; Sasa K; Okubo T; Kim Y; Mano H; Saito T
Clin Orthop Relat Res; 2021 Apr; 479(4):838-852. PubMed ID: 33196586
[TBL] [Abstract][Full Text] [Related]
7. Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK.
Mariño-Enríquez A; Wang WL; Roy A; Lopez-Terrada D; Lazar AJ; Fletcher CD; Coffin CM; Hornick JL
Am J Surg Pathol; 2011 Jan; 35(1):135-44. PubMed ID: 21164297
[TBL] [Abstract][Full Text] [Related]
8. The Presence of ALK Alterations and Clinical Relevance of Crizotinib Treatment in Pediatric Solid Tumors.
Felkai L; Bánusz R; Kovalszky I; Sápi Z; Garami M; Papp G; Karászi K; Varga E; Csóka M
Pathol Oncol Res; 2019 Jan; 25(1):217-224. PubMed ID: 29081033
[TBL] [Abstract][Full Text] [Related]
9. Uterine Inflammatory Myofibroblastic Neoplasms With Aggressive Behavior, Including an Epithelioid Inflammatory Myofibroblastic Sarcoma: A Clinicopathologic Study of 9 Cases.
Collins K; Ramalingam P; Euscher ED; Reques Llanos A; García A; Malpica A
Am J Surg Pathol; 2022 Jan; 46(1):105-117. PubMed ID: 34138797
[TBL] [Abstract][Full Text] [Related]
10. Rapid Response to Lorlatinib in a Patient With TFG-ROS1 Fusion Positive Inflammatory Myofibroblastic Tumor of the Chest Wall Metastatic to the Brain and Refractory to First and Second Generation ROS1 Inhibitors.
Carcamo B; Bista R; Wilson H; Reddy P; Pacheco J
J Pediatr Hematol Oncol; 2021 Jul; 43(5):e718-e722. PubMed ID: 34157012
[TBL] [Abstract][Full Text] [Related]
11. Uterine inflammatory myofibroblastic tumors in pregnant women with and without involvement of the placenta: a study of 6 cases with identification of a novel TIMP3-RET fusion.
Cheek EH; Fadra N; Jackson RA; Davila JI; Sukov WR; Uckerman MT; Clayton A; Keeney GL; Halling KC; Torres-Mora J; Schoolmeester JK
Hum Pathol; 2020 Mar; 97():29-39. PubMed ID: 31917155
[TBL] [Abstract][Full Text] [Related]
12. ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: Efficacy and side effects.
Brivio E; Zwaan CM
Pediatr Blood Cancer; 2019 May; 66(5):e27645. PubMed ID: 30697903
[TBL] [Abstract][Full Text] [Related]
13. Novel fusion sarcomas including targetable NTRK and ALK.
Chen T; Wang Y; Goetz L; Corey Z; Dougher MC; Smith JD; Fox EJ; Freiberg AS; Flemming D; Fanburg-Smith JC
Ann Diagn Pathol; 2021 Oct; 54():151800. PubMed ID: 34464935
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.
Antonescu CR; Suurmeijer AJ; Zhang L; Sung YS; Jungbluth AA; Travis WD; Al-Ahmadie H; Fletcher CD; Alaggio R
Am J Surg Pathol; 2015 Jul; 39(7):957-67. PubMed ID: 25723109
[TBL] [Abstract][Full Text] [Related]
15. A novel LRRFIP1-ALK fusion in inflammatory myofibroblastic tumor of hip and response to crizotinib.
Liu W; Duan Q; Gong L; Yang Y; Huang Z; Guo H; Niu X
Invest New Drugs; 2021 Feb; 39(1):278-282. PubMed ID: 32915420
[TBL] [Abstract][Full Text] [Related]
16. A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.
Kimbara S; Takeda K; Fukushima H; Inoue T; Okada H; Shibata Y; Katsushima U; Tsuya A; Tokunaga S; Daga H; Okuno T; Inoue T
Jpn J Clin Oncol; 2014 Sep; 44(9):868-71. PubMed ID: 25028698
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE.
Schöffski P; Kubickova M; Wozniak A; Blay JY; Strauss SJ; Stacchiotti S; Switaj T; Bücklein V; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Lee CJ; Speetjens FM; Nzokirantevye A; Neven A; Kasper B
Eur J Cancer; 2021 Oct; 156():12-23. PubMed ID: 34392187
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory Myofibroblastic Tumor of the Bladder With FN1-ALK Gene Fusion: Different Response to ALK Inhibition.
Reinhart S; Trachsel Y; Fritz C; Wagner U; Bode-Lesniewska B; John H; Pless M
Urology; 2020 Dec; 146():32-35. PubMed ID: 33007314
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.
Lovly CM; Gupta A; Lipson D; Otto G; Brennan T; Chung CT; Borinstein SC; Ross JS; Stephens PJ; Miller VA; Coffin CM
Cancer Discov; 2014 Aug; 4(8):889-95. PubMed ID: 24875859
[TBL] [Abstract][Full Text] [Related]
20. Pseudosarcomatous myofibroblastic proliferations of the urinary bladder are neoplasms characterized by recurrent FN1-ALK fusions.
Acosta AM; Demicco EG; Dal Cin P; Hirsch MS; Fletcher CDM; Jo VY
Mod Pathol; 2021 Feb; 34(2):469-477. PubMed ID: 32908253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
